CHAMPIONS ONCOLOGY, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CHAMPIONS ONCOLOGY, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Apr 30, 2019 | $2.90M | Jul 28, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $56.94M | Jul 23, 2025 |
| FY2025 | Apr 30, 2024 | $50.16M | Jul 23, 2025 |
| FY2024 | Apr 30, 2023 | $53.87M | Jul 19, 2024 |
| FY2023 | Apr 30, 2022 | $49.11M | Jul 24, 2023 |
| FY2022 | Apr 30, 2021 | $41.04M | Jul 22, 2022 |
| FY2021 | Apr 30, 2020 | $32.12M | Jul 26, 2021 |
| FY2020 | Apr 30, 2019 | $27.07M | Jul 28, 2020 |
| FY2019 | Apr 30, 2018 | $20.24M | Jul 29, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $4.70M | Jul 23, 2025 |
| FY2025 | Apr 30, 2024 | ($7.28M) | Jul 23, 2025 |
| FY2024 | Apr 30, 2023 | ($5.34M) | Jul 19, 2024 |
| FY2023 | Apr 30, 2022 | $548.0K | Jul 24, 2023 |
| FY2022 | Apr 30, 2021 | $362.0K | Jul 22, 2022 |
| FY2021 | Jan 31, 2021 | $959.0K | Jul 26, 2021 |
| FY2021 | Apr 30, 2020 | ($2.09M) | Jul 26, 2021 |
| FY2020 | Apr 30, 2019 | $128.0K | Jul 28, 2020 |
| FY2019 | Apr 30, 2018 | ($1.48M) | Jul 29, 2019 |
| FY2018 | Apr 30, 2017 | ($6.88M) | Jul 30, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $4.55M | Jul 23, 2025 |
| FY2025 | Apr 30, 2024 | ($7.36M) | Jul 23, 2025 |
| FY2024 | Apr 30, 2023 | ($5.26M) | Jul 19, 2024 |
| FY2023 | Apr 30, 2022 | $607.0K | Jul 24, 2023 |
| FY2022 | Apr 30, 2021 | $366.0K | Jul 22, 2022 |
| FY2021 | Jan 31, 2021 | $982.0K | Jul 26, 2021 |
| FY2021 | Apr 30, 2020 | ($1.92M) | Jul 26, 2021 |
| FY2020 | Apr 30, 2019 | $270.0K | Jul 28, 2020 |
| FY2019 | Apr 30, 2018 | ($1.35M) | Jul 29, 2019 |
| FY2018 | Apr 30, 2017 | ($6.81M) | Jul 30, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $6.83M | Jul 23, 2025 |
| FY2025 | Apr 30, 2024 | $9.54M | Jul 23, 2025 |
| FY2024 | Apr 30, 2023 | $11.55M | Jul 19, 2024 |
| FY2023 | Apr 30, 2022 | $9.37M | Jul 24, 2023 |
| FY2022 | Apr 30, 2021 | $7.20M | Jul 22, 2022 |
| FY2021 | Apr 30, 2020 | $5.85M | Jul 26, 2021 |
| FY2020 | Apr 30, 2019 | $4.80M | Jul 28, 2020 |
| FY2019 | Apr 30, 2018 | $4.40M | Jul 29, 2019 |
| FY2018 | Apr 30, 2017 | $4.29M | Jul 30, 2018 |
| FY2017 | Apr 30, 2016 | $4.19M | Jul 28, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $7.39M | Jul 23, 2025 |
| FY2025 | Apr 30, 2024 | ($6.14M) | Jul 23, 2025 |
| FY2024 | Apr 30, 2023 | $3.97M | Jul 19, 2024 |
| FY2023 | Apr 30, 2022 | $6.50M | Jul 24, 2023 |
| FY2022 | Apr 30, 2021 | ($1.68M) | Jul 22, 2022 |
| FY2021 | Apr 30, 2020 | $2.91M | Jul 26, 2021 |
| FY2020 | Apr 30, 2019 | $1.86M | Jul 28, 2020 |
| FY2019 | Apr 30, 2018 | ($1.23M) | Jul 29, 2019 |
| FY2018 | Apr 30, 2017 | ($2.84M) | Jul 30, 2018 |
| FY2017 | Apr 30, 2016 | ($6.41M) | Jul 28, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $389.0K | Jul 23, 2025 |
| FY2025 | Apr 30, 2024 | $836.0K | Jul 23, 2025 |
| FY2024 | Apr 30, 2023 | $2.87M | Jul 19, 2024 |
| FY2023 | Apr 30, 2022 | $2.38M | Jul 24, 2023 |
| FY2022 | Apr 30, 2021 | $3.28M | Jul 22, 2022 |
| FY2021 | Apr 30, 2020 | $2.22M | Jul 26, 2021 |
| FY2020 | Apr 30, 2019 | $834.0K | Jul 28, 2020 |
| FY2019 | Apr 30, 2018 | $1.23M | Jul 29, 2019 |
| FY2018 | Apr 30, 2017 | $766.0K | Jul 30, 2018 |
| FY2017 | Apr 30, 2016 | $322.0K | Jul 28, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $32.34M | Jul 23, 2025 |
| FY2025 | Apr 30, 2024 | $26.13M | Jul 23, 2025 |
| FY2024 | Apr 30, 2023 | $34.31M | Jul 19, 2024 |
| FY2023 | Apr 30, 2022 | $35.38M | Jul 24, 2023 |
| FY2022 | Apr 30, 2021 | $27.59M | Jul 22, 2022 |
| FY2021 | Apr 30, 2020 | $20.75M | Jul 26, 2021 |
| FY2020 | Apr 30, 2019 | $11.27M | Jul 28, 2020 |
| FY2019 | Apr 30, 2018 | $8.08M | Jul 29, 2019 |
| FY2018 | Apr 30, 2017 | $8.01M | Jul 30, 2018 |
| FY2017 | Apr 30, 2016 | $5.78M | Jul 28, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $28.57M | Jul 23, 2025 |
| FY2025 | Apr 30, 2024 | $28.04M | Jul 23, 2025 |
| FY2024 | Apr 30, 2023 | $29.68M | Jul 19, 2024 |
| FY2023 | Apr 30, 2022 | $26.28M | Jul 24, 2023 |
| FY2022 | Apr 30, 2021 | $20.16M | Jul 22, 2022 |
| FY2021 | Jan 31, 2021 | $17.17M | Jul 26, 2021 |
| FY2021 | Apr 30, 2020 | $15.65M | Jul 26, 2021 |
| FY2020 | Apr 30, 2019 | $9.03M | Jul 28, 2020 |
| FY2019 | Apr 30, 2018 | $8.08M | Jul 29, 2019 |
| FY2018 | Apr 30, 2017 | $7.61M | Jul 30, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $3.77M | Jul 23, 2025 |
| FY2025 | Apr 30, 2024 | ($1.90M) | Jul 23, 2025 |
| FY2025 | Apr 30, 2023 | $4.64M | Jul 23, 2025 |
| FY2024 | Apr 30, 2022 | $9.10M | Jul 19, 2024 |
| FY2023 | Apr 30, 2021 | $7.43M | Jul 24, 2023 |
| FY2021 | Jan 31, 2021 | $8.09M | Jul 26, 2021 |
| FY2022 | Apr 30, 2020 | $5.10M | Jul 22, 2022 |
| FY2021 | Apr 30, 2019 | $2.14M | Jul 26, 2021 |
| FY2020 | Apr 30, 2018 | $3.0K | Jul 28, 2020 |
| FY2019 | Apr 30, 2017 | $400.0K | Jul 29, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $335.0K | Jul 23, 2025 |
| FY2025 | Apr 30, 2024 | $335.0K | Jul 23, 2025 |
| FY2024 | Apr 30, 2023 | $335.0K | Jul 19, 2024 |
| FY2023 | Apr 30, 2022 | $335.0K | Jul 24, 2023 |
| FY2022 | Apr 30, 2021 | $335.0K | Jul 22, 2022 |
| FY2021 | Apr 30, 2020 | $335.0K | Jul 26, 2021 |
| FY2020 | Apr 30, 2019 | $669.0K | Jul 28, 2020 |
| FY2019 | Apr 30, 2018 | $669.0K | Jul 29, 2019 |
| FY2018 | Apr 30, 2017 | $669.0K | Jul 30, 2018 |
| FY2017 | Apr 30, 2016 | $669.0K | Jul 28, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | ($79.89M) | Jul 23, 2025 |
| FY2025 | Apr 30, 2024 | ($84.59M) | Jul 23, 2025 |
| FY2024 | Apr 30, 2023 | ($77.32M) | Jul 19, 2024 |
| FY2023 | Apr 30, 2022 | ($71.98M) | Jul 24, 2023 |
| FY2022 | Apr 30, 2021 | ($72.53M) | Jul 22, 2022 |
| FY2021 | Jan 31, 2021 | ($71.64M) | Jul 26, 2021 |
| FY2021 | Apr 30, 2020 | ($72.89M) | Jul 26, 2021 |
| FY2020 | Apr 30, 2019 | ($70.70M) | Jul 28, 2020 |
| FY2019 | Apr 30, 2018 | ($70.83M) | Jul 29, 2019 |
| FY2018 | Apr 30, 2017 | ($69.35M) | Jul 30, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Apr 30, 2019 | $3.24M | Jul 29, 2019 |
| FY2019 | Apr 30, 2018 | $856.0K | Jul 29, 2019 |
| FY2018 | Apr 30, 2017 | $3.30M | Jul 30, 2018 |
| FY2018 | Apr 30, 2016 | $2.59M | Jul 30, 2018 |
| FY2017 | Apr 30, 2015 | $9.36M | Jul 28, 2017 |
| FY2016 | Apr 30, 2014 | $5.89M | Jul 29, 2016 |
| FY2015 | Apr 30, 2013 | $9.56M | Jul 29, 2015 |
| FY2014 | Apr 30, 2012 | $4.75M | Jul 28, 2014 |
| FY2013 | Apr 30, 2011 | $10.46M | Jul 26, 2013 |
| FY2012 | Apr 30, 2010 | $2.57M | Jul 18, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | 0 | Jul 23, 2025 |
| FY2025 | Apr 30, 2024 | 0 | Jul 23, 2025 |
| FY2024 | Apr 30, 2023 | 0 | Jul 19, 2024 |
| FY2023 | Apr 30, 2022 | 0 | Jul 24, 2023 |
| FY2022 | Apr 30, 2021 | 0 | Jul 22, 2022 |
| FY2021 | Jan 31, 2021 | 0 | Jul 26, 2021 |
| FY2021 | Apr 30, 2020 | 0 | Jul 26, 2021 |
| FY2020 | Apr 30, 2019 | 0 | Jul 28, 2020 |
| FY2019 | Apr 30, 2018 | 0 | Jul 29, 2019 |
| FY2016 | Apr 30, 2016 | (1) | Jul 29, 2016 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | 0 | Jul 23, 2025 |
| FY2025 | Apr 30, 2024 | 0 | Jul 23, 2025 |
| FY2024 | Apr 30, 2023 | 0 | Jul 19, 2024 |
| FY2023 | Apr 30, 2022 | 0 | Jul 24, 2023 |
| FY2022 | Apr 30, 2021 | 0 | Jul 22, 2022 |
| FY2021 | Jan 31, 2021 | 0 | Jul 26, 2021 |
| FY2021 | Apr 30, 2020 | 0 | Jul 26, 2021 |
| FY2020 | Apr 30, 2019 | 0 | Jul 28, 2020 |
| FY2019 | Apr 30, 2018 | 0 | Jul 29, 2019 |
| FY2016 | Apr 30, 2016 | (1) | Jul 29, 2016 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | 13.78M | Jul 23, 2025 |
| FY2025 | Apr 30, 2024 | 13.59M | Jul 23, 2025 |
| FY2024 | Apr 30, 2023 | 13.54M | Jul 19, 2024 |
| FY2023 | Apr 30, 2022 | 13.52M | Jul 24, 2023 |
| FY2022 | Apr 30, 2021 | 13.41M | Jul 22, 2022 |
| FY2021 | Apr 30, 2020 | 12.73M | Jul 26, 2021 |
| FY2020 | Apr 30, 2019 | 11.62M | Jul 28, 2020 |
| FY2019 | Apr 30, 2018 | 11.00M | Jul 29, 2019 |
| FY2018 | Apr 30, 2017 | 10.98M | Jul 30, 2018 |
| FY2017 | Apr 30, 2016 | 8.70M | Jul 28, 2017 |